Rate My Professor Andrew Jamieson

Professor Andrew Jamieson is Professor of Chemical Biology in the School of Chemistry at the University of Glasgow. Born in Glasgow and raised in Strathaven, Scotland, he obtained a first-class BSc Honours degree in Chemistry with Medicinal Chemistry from the University of Glasgow in 2003. He completed his PhD there in 2007 under the supervision of Dr. Andrew Sutherland, investigating a substrate-directed palladium-catalysed aza-Claisen rearrangement and its application to natural product synthesis. Jamieson then pursued postdoctoral research, first as a fellowship with Professor William Lubell at the University of Montreal, Canada, in 2007, where he developed methods to scan peptides for secondary structure, focusing on bioactive conformations of GHRP-6 and rytvela. In 2008, he joined Professor Andrew Hamilton FRS at Yale University, USA, working on peptide beta-strand mimetics, and continued this collaboration at the University of Oxford, UK, in 2009. In August 2010, he was appointed Lecturer in the Centre for Chemical Biology, Department of Chemistry, at the University of Leicester. He returned to the University of Glasgow as Senior Lecturer in Chemical Biology in the School of Chemistry in July 2016, advanced to Reader in 2019, and was promoted to Professor in August 2022. In 2022, he co-founded Keltic Pharma Therapeutics Ltd. with University of Glasgow colleagues to develop curative treatments for Plasmodium falciparum malaria and GPCR-targeted therapies using the PEPSMOL platform.

The Jamieson Group's research centers on designing and synthesizing peptides and peptidomimetics to elucidate disease mechanisms in cancer and Alzheimer’s disease, selectively regulate ion channels with conotoxins for severe pain treatment, and develop inhibitors for deubiquitinase and histone deacetylase enzymes, alongside probing toxic amyloid protein structures. Notable publications include 'Insights into the activation mechanism of class I HDAC complexes by inositol phosphates' (Nature Communications, 2016), 'Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo' (Scientific Reports, 2018), 'Peptide Scanning for Studying Structure–Activity Relationships in Drug Discovery' (Chemical Biology & Drug Design, 2013), and recent works such as 'Shaping antimalarials: a geometry-first approach to PfCLK3 covalent inhibitors' (Journal of Medicinal Chemistry, 2026) and 'Development of potent PfCLK3 inhibitors based on TCMDC-135051' (2020). He received the Royal Society of Chemistry Chemical Biology and Bioorganic Group Lectureship in 2023. Jamieson contributes to EPSRC panels, the SCI Industry Young Chemists Panel, RSC Chemical Biology and Bioorganic Group Committee, and ANR grant reviews. He teaches Level-1 Organic Chemistry and Level-3 Biotransformations.